Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980631 | 0.93 | HPSE (0.40) | HPSEGLP1RFAAHCNR1CNR2 | |
| SCHEMBL23157910 | 0.89 | CRBN (0.37) | GLP1REPHX2 | |
| SCHEMBL23157890 | 0.89 | CRBN (0.37) | GLP1REPHX2 | |
| SCHEMBL17746982 | 0.88 | KDM4E (0.40) | GLP1REPHX2 | |
| SCHEMBL30980725 | 0.88 | KDM4E (0.40) | GLP1REPHX2 | |
| SCHEMBL27016022 | 0.88 | HPSE (0.37) | HPSEGLP1RFAAHLPAR1LPAR2 | |
| SCHEMBL23158184 | 0.87 | CRBN (0.38) | GLP1R | |
| SCHEMBL25495673 | 0.87 | CRBN (0.38) | GLP1R | |
| SCHEMBL30881385 | 0.86 | HPSE (0.38) | HPSEGLP1RLPAR1LPAR2ENPP2 | |
| SCHEMBL23157853 | 0.86 | TSHR (0.38) | GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | HPSE 2920/4885GLP1R 3051/4885EPHX2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.